These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 15050632)
1. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Perni RB; Farmer LJ; Cottrell KM; Court JJ; Courtney LF; Deininger DD; Gates CA; Harbeson SL; Kim JL; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao BG; Schairer WC; Tung RD; Van Drie JH; Wilson K; Thomson JA Bioorg Med Chem Lett; 2004 Apr; 14(8):1939-42. PubMed ID: 15050632 [TBL] [Abstract][Full Text] [Related]
2. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390 [TBL] [Abstract][Full Text] [Related]
4. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623 [TBL] [Abstract][Full Text] [Related]
5. Potent triazolyl-proline-based inhibitors of HCV NS3 protease. Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339 [TBL] [Abstract][Full Text] [Related]
6. NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent. Goudreau N; Cameron DR; Bonneau P; Gorys V; Plouffe C; Poirier M; Lamarre D; Llinas-Brunet M J Med Chem; 2004 Jan; 47(1):123-32. PubMed ID: 14695826 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents. Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405 [TBL] [Abstract][Full Text] [Related]
8. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
9. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors. Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109 [TBL] [Abstract][Full Text] [Related]
11. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement. Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919 [TBL] [Abstract][Full Text] [Related]
12. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
13. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105 [TBL] [Abstract][Full Text] [Related]
14. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. Wyss DF; Arasappan A; Senior MM; Wang YS; Beyer BM; Njoroge FG; McCoy MA J Med Chem; 2004 May; 47(10):2486-98. PubMed ID: 15115392 [TBL] [Abstract][Full Text] [Related]
15. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease. Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency. Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332 [TBL] [Abstract][Full Text] [Related]
17. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H; Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V Bioorg Med Chem Lett; 2006 Aug; 16(15):3960-5. PubMed ID: 16730985 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982 [TBL] [Abstract][Full Text] [Related]
19. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bogen S; Arasappan A; Pan W; Ruan S; Padilla A; Saksena AK; Girijavallabhan V; Njoroge FG Bioorg Med Chem Lett; 2008 Jul; 18(14):4219-23. PubMed ID: 18547808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]